| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Etiology Program, Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI and 2 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA
Requests for reprints: Loïc Le Marchand, Etiology Program, Cancer Research Center of Hawaii, University of Hawaii, 1236 Lauhala Street, Suite 407, Honolulu, HI 96813. Phone: (808) 586-2988; Fax: (808) 586-2082. E-mail: loic{at}crch.hawaii.edu
Laboratory studies suggest a dual role for the transforming growth factor-ß (TGF-ß) signaling pathway in breast cancer. The normal antiproliferative activity of TGF-ß in early breast tumor development is replaced by a promoting effect in later stages. A T29C transition polymorphism in the TGFB1 gene has been associated with higher circulating TGF-ß1 levels, and inconsistently with breast cancer risk in three recent studies. We tested the association of this variant with invasive breast cancer in a case-control study of 1123 cases and 2314 controls nested in the Multiethnic Cohort (MEC) Study. This study is a large prospective study being conducted in Hawaii and Los Angeles that includes Japanese, white, African American, Latino, and Native Hawaiian women who were predominantly postmenopausal at baseline. After adjustment for breast cancer risk factors, the odds ratio (OR) and 95% confidence interval (95% CI) for the TGFB1 29 CC genotype was 0.95 (95% confidence interval: 0.76–1.18), compared to the TT genotype. Analyses stratified by race/ethnicity, stage, or age category did not reveal any association of this variant with breast cancer. Given the strong biological rationale and the scarce and divergent epidemiologic data to date, additional investigations of the relationship between breast cancer and genetic variants in the TGF-ß signaling pathway appear warranted.
This article has been cited by other articles:
|
|
 |
|
  B. S. Saltzman, J. F. Yamamoto, R. Decker, L. Yokochi, A. G. Theriault, T. M. Vogt, and L. Le Marchand Association of Genetic Variation in the Transforming Growth Factor {beta}-1 Gene with Serum Levels and Risk of Colorectal Neoplasia Cancer Res., February 15, 2008; 68(4): 1236 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Feigelson, A. V. Patel, W. R. Diver, V. L. Stevens, M. J. Thun, and E. E. Calle Transforming Growth Factor {beta} Receptor Type I and Transforming Growth Factor {beta}1 Polymorphisms Are Not Associated with Postmenopausal Breast Cancer. Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1236 - 1237. [Full Text] [PDF]
|
|
|
|
 |
|
 D L Mattey, N Nixon, P T Dawes, and J Kerr Association of polymorphism in the transforming growth factor {beta}1 gene with disease outcome and mortality in rheumatoid arthritis Ann Rheum Dis, August 1, 2005; 64(8): 1190 - 1194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shin, X.-O. Shu, Q. Cai, Y.-T. Gao, and W. Zheng Genetic Polymorphisms of the Transforming Growth Factor-{beta}1 Gene and Breast Cancer Risk: A Possible Dual Role at Different Cancer Stages Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1567 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. G. Kaklamani, L. Baddi, J. Liu, D. Rosman, S. Phukan, C. Bradley, C. Hegarty, B. McDaniel, A. Rademaker, C. Oddoux, et al. Combined Genetic Assessment of Transforming Growth Factor-{beta} Signaling Pathway Variants May Predict Breast Cancer Risk Cancer Res., April 15, 2005; 65(8): 3454 - 3461. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
